sn

SN-008 is a less active analog SN-011 which is a STING antagonist. SN-008 can be used as a negative control.

1,2-Distearoyl-sn-glycero-3-phosphorylethanolamine (1,2-DSPE) is a phosphatidylethanolamine (PE or GPEtn). The stearic acid moieties are derived from animal fats, cocoa butter, and sesame oil. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.

1-Myristoyl-2-stearoyl-sn-glycero-3-phosphocholine is an endogenous metabolite. 1-Myristoyl-2-stearoyl-sn-glycero-3-phosphocholine is a non-limiting exemplary phosphatidyl choline.

SN 2 is a novel and potent TRPML3 ion channel activator(EC50 of 1.8±0.13 μM).

SN 6 (SN6) is a selective Na+/Ca2+ exchanger (NCX) inhibitor (IC50s of NCX1: 2.9 μM , NCX2: 16 μM ,NCX3: 8.6 μM)

1,2-Dipalmitoyl-sn-glycerol 3-phosphate (a phosphatidic acid) is a human endogenous metabolite.

1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine is an endogenous metabolite.

CL2-SN-38, a part of the antibody-drug conjugate (ADC), can conjugate with the anti-Trop-2-humanized antibody hRS7. SN-38 is an inhibitor of DNA topoisomerase I.

SN50 is a cell permeable NF-κB translocation inhibitor.

SN50 acetate is a cell permeable inhibitor of NF-κB translocation.

CL2A-SN-38 consists of a CL2A linker and an anticancer compound, SN-38, which delivers active molecules within tumor cells and in the tumor microenvironment, often in conjunction with antibodies to make biologically active antibody-coupled reactive molecules (ADCs).

CL2A-SN-38 is a drug-linker conjugate composed of a potent a DNA Topoisomerase I inhibitor SN-38 and a linker CL2A to make antibody drug conjugate (ADC).. CL2A-SN-38 is composed of a potent a DNA Topoisomerase I inhibitor SN-38 and a linker CL2A to make antibody drug conjugate (ADC). CL2A-SN-38 provides significant and specific antitumor effects against a range of human solid tumor types. CL2A is a noncleavable complicated PEG8- and triazole-containing PABC-peptide-mc linker. CL2A is cleavable through pH sensitivity, giving rise to bystander effect, and binds the antibody at a cysteine residue via a disulfide bond. .

MAC glucuronide phenol-linked SN-38, a pH-sensitive lactone and DNA topoisomerase I inhibitor drug linker, exhibits cytotoxicity in L540cy and Ramos cells, with IC50 values of 113 ng/mL and 67 ng/mL, respectively[1].

MAC glucuronide α-hydroxy lactone-linked SN-38 (Topoisomerase I inhibitor) is a cytotoxic drug linker that maintains a stabilized lactone form, demonstrating efficacy against L540cy and Ramos cells with IC50 values of 99 and 105 ng/mL, respectively[1].

2-γ-Linolenoyl-1,3-dilinoleoyl-sn-glycerol is a triglyceride.

1-Myristoyl-2-hydroxy-sn-glycero-3-phosphate sodium is a salt form compound.1-Myristoyl-2-hydroxy-sn-glycero-3-phosphate is a lipid and endogenous metabolite related to LPA (lysophosphatidic acid).

1-Oleoyl-sn-glycero-2,3-cyclic-phosphate ammonium (18:1 Cyclic LPA) is a cyclic lysophosphatidic acid used in lipid vesicle (liposome) formation.

1,2-Dipalmitoleoyl-sn-glycero-3-phosphoethanolamine (16:1 PE) is a phosphatidylethanolamine that can enhance the activities of PP2A and PTP1B in malignant pleural mesothelioma cells. Additionally, 1,2-Dipalmitoleoyl-sn-glycero-3-phosphoethanolamine induces apoptosis in NCI-H28 malignant pleural mesothelioma cells.

1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA is a phospholipid that contains arachidonic acid at the sn-1 position, serving as a precursor to 1-Monoarachidin. It binds with the LPA2/EDG4 receptor and can inhibit the secretion of TNF-α and IL-6 induced by LPS in wild-type dendritic cells but does not affect Lpa2-/- dendritic cells. Additionally, it reduces the differentiation of HT-29 human colon cancer cells into goblet cells in the presence of sodium butyrate.

1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA (sodium) [1-Arachidonoyl-sn-glycerol 3-phosphate (sodium)] is a phospholipid containing arachidonic acid at the sn-1 position. It binds to the LPA2/EDG4 receptor with an EC50 of 10 nM and is present in the rat brain, representing 37% of arachidonic acid lysophosphatidic acid species. This compound serves as a precursor to 1-arachidonoyl-sn-glycerol and inhibits the secretion of TNF-α and IL-6 from dendritic cells stimulated by wild-type LPS. Additionally, 1-arachidonoyl-2-hydroxy-sn-glycero-3-PA (sodium) can suppress the differentiation of HT-29 colon cancer cells into goblet cells in the presence of sodium butyrate.

1-(1(Z)-Hexadecenyl)-2-linoleoyl-sn-glycero-3-phosphocholine is a plasmalogen characterized by the presence of 1(Z)-hexadecenoic acid and linoleic acid at the sn-1 and sn-2 positions, respectively. It counteracts lead-induced reductions in cell viability and suppresses increases in reactive oxygen species (ROS) and oxidized phospholipids in HepG2 hepatocytes. In dogs with myxomatous mitral valve disease, serum levels of this compound decrease when their diet is enriched with medium chain triglycerides, fish oil, carnitine precursors, magnesium, and antioxidants.

1,2-Dilauroyl-sn-glycerol ((S)-1,2-Dilaurin) is primarily composed of the interaction of 1,2-dilauroyl-sn-glycerol (1,2-DLG) with phosphatidylcholine (PC) bilayers.

SN 003 is a CRF1 antagonist.

SN34037 is a specific Aldo-keto reductase 1C3 (AKR1C3) inhibitor capable of reducing PR-104A to PR-104H and inhibiting the cytotoxic activity of PR-104A, suitable for studying PR-104A-responsive leukaemia.